The relationship between ABO blood group and the risk of bleeding during vitamin K antagonist treatment.
Garcia
A A
AA
van der Heijden
J F
JF
Meijers
J C M
JC
Rosendaal
F R
FR
Reitsma
P H
PH
D000017:ABO Blood-Group System / Q000235:genetics; D000925:Anticoagulants / Q000009:adverse effects*; D016022:Case-Control Studies; D005169:Factor VIII / Q000378:metabolism; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D012307:Risk Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors; D014859:Warfarin / Q000009:adverse effects; D014841:von Willebrand Factor / Q000378:metabolism
D000017:ABO Blood-Group System; D000925:Anticoagulants; D014841:von Willebrand Factor; D014812:Vitamin K; D014859:Warfarin; C078147:F8 protein, human; D005169:Factor VIII